Multiple end‐point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: Implications for predictive testing

Abstract excerpt

Systemic chemotherapy is extensively used in cancer therapy, however, for many treatments' response rates are limited. Furthermore, certain regimens are frequently associated with significant morbidity and occasional mortality. Consequently, when alternative options exist, it is desirable to reserve a particular chemotherapy for those patients whose tumours will respond. Therefore, attention is turning to the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinogens and Genotoxicity Assessment
• Share to Chemotherapy-induced organ toxicity mitigation
• Share to DNA Repair Mechanisms